In last trading session, Immunome Inc (NASDAQ:IMNM) saw 1.33 million shares changing hands with its beta currently measuring 1.92. Company’s recent per share price level of $8.52 trading at $0.02 or 0.24% at ring of the bell on the day assigns it a market valuation of $740.82M. That closing price of IMNM’s stock is at a discount of -97.3% from its 52-week high price of $16.81 and is indicating a premium of 39.55% from its 52-week low price of $5.15. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.16 million shares which gives us an average trading volume of 1.18 million if we extend that period to 3-months.
For Immunome Inc (IMNM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.57 in the current quarter.
Immunome Inc (NASDAQ:IMNM) trade information
Upright in the green during last session for gaining 0.24%, in the last five days IMNM remained trading in the green while hitting it’s week-highest on Thursday, 04/24/25 when the stock touched $8.52 price level, adding 4.05% to its value on the day. Immunome Inc’s shares saw a change of -19.77% in year-to-date performance and have moved 18.83% in past 5-day. Immunome Inc (NASDAQ:IMNM) showed a performance of 22.59% in past 30-days. Number of shares sold short was 11.13 million shares which calculate 8.82 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 33 to the stock, which implies a rise of 74.18% to its current value. Analysts have been projecting 23 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would drop -169.95% in reaching the projected high whereas dropping to the targeted low would mean a loss of -169.95% for stock’s current value.
Immunome Inc (IMNM) estimates and forecasts
This year revenue growth is estimated to fall -78.53% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 457.14k for the same. And 7 analysts are in estimates of company making revenue of 457.14k in the next quarter. Company posted 1.03M and 2.36M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -38.15% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 48.00% while estimates for its earnings growth in next 5 years are of 21.19%.
Immunome Inc (NASDAQ:IMNM)’s Major holders
Insiders are in possession of 16.23% of company’s total shares while institution are holding 58.07 percent of that, with stock having share float percentage of 69.31%. Investors also watch the number of corporate investors in a company very closely, which is 58.07% institutions for Immunome Inc that are currently holding shares of the company. REDMILE GROUP, LLC is the top institutional holder at IMNM for having 4.89 million shares of worth $59.16 million. And as of 2024-06-30, it was holding 8.1579 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 4.21 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.0257 of outstanding shares, having a total worth of $50.95 million.
On the other hand, PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund and T. Rowe Price Small-Cap Stock Fund, Inc. are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025 , the former fund manager was holding 3.07 shares of worth $26.17 million or 3.53% of the total outstanding shares. The later fund manager was in possession of 1.96 shares on Dec 31, 2024 , making its stake of worth around $16.67 million in the company or a holder of 2.25% of company’s stock.
